Alterity Therapeutics (NASDAQ:ATHE) news for Monday includes a new patent protecting its drugs pushing ATHE stock higher.
Here’s what investors in ATHE stock need to know about the Alterity Therapeutics news.
- The company has received patent approval from the United States Patent and Trademark Office (USPTO) for a new composition of matter.
- This patent covers more than 150 novel pharmaceutical compositions.
- These compositions are set to treat a range of diseases.
- That includes Parkinson’s disease, Alzheimer’s disease, and other neurodegenerative conditions.
- According to an Alterity Therapeutics news release, this will help it expand its drug development portfolio.
- That includes ATH434, which is its most advanced compound and is currently in development.
- Alterity Therapeutics notes that it submitted its patent in March of this year and it was given special focus by the USPTO.
- It’s also looking to register the patent in other regions as well.
Geoffrey Kempler, chairman and CEO of Alterity Therapeutics, said this about the news.
“There is a growing clinical and scientific focus on the implication of elevated iron in the brain of people with neurodegenerative disease. Alterity has been at the forefront of research and drug development in this area, and we have significant research to support our current and future drug development efforts.”
ATHE stock was up 124.7% as of Monday morning and is up 236.4% since the start of the year.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article.
